Literature DB >> 15521853

Review article: epidemiology and quality of life in functional gastrointestinal disorders.

L Chang1.   

Abstract

The epidemiology and health-related quality of life associated with functional gastrointestinal disorders are reviewed, with particular emphasis on irritable bowel syndrome and functional dyspepsia. The literature supports the significant world-wide prevalence of functional gastrointestinal disorders, including irritable bowel syndrome (IBS), functional dyspepsia and chronic constipation. An increased female prevalence has been demonstrated in most studies in patients with IBS and chronic constipation, but not functional dyspepsia. The female to male ratio appears to be greater in the health care-seeking population than in community populations. However, some differences in the reported general prevalence and gender-related prevalence of functional gastrointestinal disorders may be due to cultural factors and study methodology. A significant health care burden is associated with IBS, with increased out-patient services, abdominal and pelvic surgeries, and gastrointestinal- and non-gastrointestinal-related physician visits and health care costs. Health-related quality of life is impacted significantly in patients with functional gastrointestinal disorders, such as functional dyspepsia and IBS, compared with the general healthy population, as well as patients with other chronic medical conditions, such as gastro-oesophageal reflux disease and asthma. Impaired health-related quality of life has been demonstrated, in particular, in patients with moderate to severe disease seen in referral settings. The health-related quality of life appears to improve in treatment responders, or correlates with symptom improvement, with at least some treatment modalities studied in functional gastrointestinal disorders, but further studies are needed. Predictors of health-related quality of life in patients with functional gastrointestinal disorders include psychosocial factors, such as early adverse life events, and symptoms related to visceral perception, e.g. pain and chronic stress. The presence of extra-intestinal symptoms appears to have a major if not greater impact on health care visits, excess health care costs and health-related quality of life in patients with functional gastrointestinal disorders.

Entities:  

Mesh:

Year:  2004        PMID: 15521853     DOI: 10.1111/j.1365-2036.2004.02183.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  98 in total

1.  Biomagnetic techniques for evaluating gastric emptying, peristaltic contraction and transit time.

Authors:  Jose María De la Roca-Chiapas; Teodoro Cordova-Fraga
Journal:  World J Gastrointest Pathophysiol       Date:  2011-10-15

2.  Maximum tolerated volume in drinking tests with water and a nutritional beverage for the diagnosis of functional dyspepsia.

Authors:  Aldo Montaño-Loza; Max Schmulson; Sergio Zepeda-Gómez; Jose Maria Remes-Troche; Miguel Angel Valdovinos-Diaz
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

Review 3.  Slow transit constipation: a functional disorder becomes an enteric neuropathy.

Authors:  Gabrio Bassotti; Vincenzo Villanacci
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

4.  Diagnostic Utility of Carbohydrate Breath Tests for SIBO, Fructose, and Lactose Intolerance.

Authors:  Mercedes Amieva-Balmori; Enrique Coss-Adame; Nikilesh S Rao; Brisa M Dávalos-Pantoja; Satish S C Rao
Journal:  Dig Dis Sci       Date:  2019-10-15       Impact factor: 3.199

5.  Racial differences in epidemiology of irritable bowel syndrome alone, un-investigated dyspepsia alone, and "overlap syndrome" among african americans compared to Caucasians: a population-based study.

Authors:  Anil Minocha; William Chad; Wigington Do; William D Johnson
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

Review 6.  Japanese herbal medicine in functional gastrointestinal disorders.

Authors:  H Suzuki; J M Inadomi; T Hibi
Journal:  Neurogastroenterol Motil       Date:  2009-03-25       Impact factor: 3.598

7.  Measuring acceptance in irritable bowel syndrome: preliminary validation of an adapted scale and construct utility.

Authors:  Nuno Bravo Ferreira; Maria P Eugenicos; Paul Graham Morris; David T Gillanders
Journal:  Qual Life Res       Date:  2012-10-25       Impact factor: 4.147

8.  A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial.

Authors:  Solveig C Ligaarden; Lars Axelsson; Kristine Naterstad; Stian Lydersen; Per G Farup
Journal:  BMC Gastroenterol       Date:  2010-02-10       Impact factor: 3.067

9.  Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome.

Authors:  Tisha N Lunsford; Lucinda A Harris
Journal:  Int J Womens Health       Date:  2010-10-27

10.  Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells.

Authors:  Satya Prakash; Aleksandra Malgorzata Urbanska
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.